QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

Help viewing high resolution images Return to article

Fig. 6. Metabolic pathways implicated in potentiating COX-2 expression in neutrophils following A_2A receptor activation. (A) PMNs were stimulated with fMLP (upper) or LPS (lower) in the presence of ADA and of CGS 21680 (A_2AR agonist), alone or in combination with indicated metabolic inhibitors. Samples were processed for the determination of COX-2 by western immunoblotting. Bar graphs depict the expression of COX-2 protein levels, relative to those observed in PMNs stimulated in absence of metabolic inhibitors (solid black bars), as determined by densitometric analysis of the bands in three independent experiments (mean±s.e.m.; n=3). (B, C) PMNs were stimulated with fMLP (B) of LPS (C), in combination either with a membrane-permeable cAMP analog, Sp-cAMPs-am (upper), or with a mixture of an activator of adenylyl cyclase and an inhibitor of phosphodiesterase IV, RO-20-1724 and forskolin; 50 µM and 10 µM, respectively (lower), alone or in combination with the indicated metabolic inhibitors. Bar graphs depict the expression of COX-2 protein levels, relative to that observed in PMNs stimulated in absence of metabolic inhibitors, as determined by densitometric analysis of the bands in three independent experiments (mean±s.e.m.; n=3). In each panel, one typical immunoblot is shown and is representative of at least n=3 independent experiments performed in identical conditions with different donors. *Statistically different from cells treated with stimulus+ADA+cAMP-elevating agents.

Return to article